Emergent Biosolutions Total Assets 2010-2022 | EBS

Emergent Biosolutions total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Emergent Biosolutions Annual Total Assets
(Millions of US $)
2021 $2,959
2020 $2,883
2019 $2,327
2018 $2,229
2017 $1,070
2016 $970
2015 $1,037
2014 $939
2013 $627
2012 $564
2011 $547
2010 $500
2009 $345
Emergent Biosolutions Quarterly Total Assets
(Millions of US $)
2022-06-30 $2,735
2022-03-31 $2,780
2021-12-31 $2,959
2021-09-30 $2,868
2021-06-30 $2,915
2021-03-31 $2,900
2020-12-31 $2,883
2020-09-30 $2,616
2020-06-30 $2,466
2020-03-31 $2,279
2019-12-31 $2,327
2019-09-30 $2,334
2019-06-30 $2,321
2019-03-31 $2,154
2018-12-31 $2,229
2018-09-30 $1,174
2018-06-30 $1,139
2018-03-31 $1,068
2017-12-31 $1,070
2017-09-30 $1,024
2017-06-30 $970
2017-03-31 $952
2016-12-31 $970
2016-09-30 $932
2016-06-30 $1,056
2016-03-31 $1,036
2015-12-31 $1,037
2015-09-30 $977
2015-06-30 $943
2015-03-31 $918
2014-12-31 $939
2014-09-30 $869
2014-06-30 $837
2014-03-31 $823
2013-12-31 $627
2013-09-30 $595
2013-06-30 $556
2013-03-31 $538
2012-12-31 $564
2012-09-30 $540
2012-06-30 $527
2012-03-31 $515
2011-12-31 $547
2011-09-30 $513
2011-06-30 $494
2011-03-31 $471
2010-12-31 $500
2010-09-30 $366
2010-06-30 $346
2010-03-31 $343
2009-12-31 $345
2009-09-30 $317
2009-06-30 $326
2009-03-31 $304
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.040B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.873B 0.00
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Enzo Biochem (ENZ) United States $0.105B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00